QLT Inc. – Product Pipeline Review – 2012 by GlobalMarketsDirect

VIEWS: 10 PAGES: 65

The report provides data on the QLT Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, QLT Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from QLT Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

More Info
									                    QLT Inc. – Product Pipeline Review – 2012

                                                                                          Reference Code: GMDHC02236CDB
                                                                                                 Publication Date: MAY 2012




QLT Inc. – Product Pipeline Review – 2012                                                 GMDHC02236CDB / Published MAY 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                               Page(1)
QLT Inc. – Product Pipeline Review




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 5
QLT Inc. Snapshot ............................................................................................................................................................................. 6
    QLT Inc. Overview ......................................................................................................................................................................... 6
    Key Information ............................................................................................................................................................................. 6
    Key Facts....................................................................................................................................................................................... 6
QLT Inc. – Research and Development Overview ............................................................................................................................. 7
    Key Therapeutic Areas .................................................................................................................................................................. 7
QLT Inc. – Pipeline Review ................................................................................................................................................................ 9
    Pipeline Products by Stage of Development ................................................................................................................................. 9
    Pipeline Products – Monotherapy ............................................................................................................................................... 10
    Pipeline Products – Combination Treatment Modalities .............................................................................................................. 11
QLT Inc. – Pipeline Products Glance ............................................................................................................................................... 12
    QLT Inc. Clinical Stage Pipeline Products ................................................................................................................................... 12
        Phase II Products/Combination Treatment Modalities ............................................................................................................ 12
        Phase I Products/Combination Treatment Modalities ............................................................................................................. 13
QLT Inc. – Drug Profiles ................................................................................................................................................................... 14
    Latanoprost Punctal Plug Delivery System .................................................................................................................................. 14
        Product Description................................................................................................................................................................. 14
        Mechanism of Action ............................................................................................................................................................... 14
        R&D Progress ......................................................................................................................................................................... 14
    Lemuteporfin................................................................................................................................................................................ 16
        Product Description................................................................................................................................................................. 16
        Mechanism of Action ............................................................................................................................................................... 16
        R&D Progress ......................................................................................................................................................................... 16
    QLT091001.................................................................................................................................................................................. 17
        Product Description................................................................................................................................................................. 17
        Mechanism of Action ............................................................................................................................................................... 17
        R&D Progress ......................................................................................................................................................................... 17
    Visudyne + Lucentis + Dexamethasone ...................................................................................................................................... 19
        Product Description................................................................................................................................................................. 19
        Mechanism of Action ............................................................................................................................................................... 19
        R&D Progress ......................................................................................................................................................................... 19
QLT Inc. – Pipeline Analysis............................................................................................................................................................. 21
    QLT Inc. – Pipeline Products by Therapeutic Class .................................................................................................................... 21
    QLT Inc. – Pipeline Products By Target ...................................................................................................................................... 22
    QLT Inc. – Pipeline Products by Route of Administration ............................................................................................................ 23
    QLT Inc. – Pipeline Products By Mechanism of Action................................................................................................................ 24
QLT Inc. – Recent Pipeline Updates ............................................................................................................................................... 25
QLT Inc. - Dormant Projects ............................................................................................................................................................. 27
QLT Inc. - Discontinued Pipeline Products ....................................................................................................................................... 28



QLT Inc. – Product Pipeline Review – 2012                                                                                              GMDHC02236CDB / Published MAY 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                      Page(2)
QLT Inc. – Product Pipeline Review



    Discontinued Pipeline Product Profiles ........................................................................................................................................ 28
         QLT091568 ............................................................................................................................................................................. 28
         Tariquidar ................................................................................................................................................................................ 28
         Tariquidar + Paclitaxel + Carboplatin ...................................................................................................................................... 28
         Tariquidar + Vinorelbine .......................................................................................................................................................... 29
QLT Inc. – Company Statement ....................................................................................................................................................... 30
QLT Inc. – Locations And Subsidiaries ............................................................................................................................................ 32
    Head Office.................................................................................................................................................................................. 32
    Other Locations & Subsidiaries ................................................................................................................................................... 32
QLT Inc., Recent Developments ...................................................................................................................................................... 33
    QLT Inc.- Press Release ............................................................................................................................................................. 33
         Apr 02, 2012: QLT To Present Data From Phase Ib Trial Of QLT091001 At ARVO ............................................................... 33
         Mar 19, 2012: QLT Receives Orphan Drug Designation For Visudyne For Treatment of Central Serous Chorioretinopathy . 33
         Mar 01, 2012: QLT Announces Positive Preliminary Results From Phase Ib Trial Of QLT091001 In Subjects With Retinitis
         Pigmentosa ............................................................................................................................................................................. 34
         Dec 15, 2009: QLT Inc. Initiates Phase Ib Trial Study Of QLT091001 For The Treatment Of Leber Congenital Amaurosis
         (LCA) ...................................................................................................................................................................................... 35
         Jul 28, 2009: Qlt Announces Interim Data From A Phase II Clinical Trial And A Device Study For A Punctal Plug Drug
         Delivery System ...................................................................................................................................................................... 36
         Mar 12, 2009: QLT Announces Completion Of Phase Ia Safety Trial Of Its Synthetic Retinoid Product QLT091001............. 37
Financial Deals Landscape .............................................................................................................................................................. 39
    QLT Inc., Deals Summary ........................................................................................................................................................... 39
QLT Inc., Pharmaceuticals & Healthcare, Deal Details .................................................................................................................... 40
    Asset Transactions ...................................................................................................................................................................... 40
         QLT Acquires OT-730 From Othera Pharma .......................................................................................................................... 40
         QLT Acquires US Rights Of Visudyne From Novartis ............................................................................................................. 42
         QLT Acquires Full Rights To Aczone From Astellas ............................................................................................................... 43
    Partnerships ................................................................................................................................................................................ 45
         QLT Ophthalmics Enters Into Co-Promotion Agreement With Quantel Medical And Quantel USA ........................................ 45
         QLT Signs Agreement With Wilmer Eye Institute.................................................................................................................... 46
         Array BioPharma Enters Into Co-Development Agreement With QLT .................................................................................... 47
    Licensing Agreements ................................................................................................................................................................. 48
         QLT Enters Into Licensing Agreement With Reckitt Benckiser ............................................................................................... 48
         QLT Enters Into Licensing Agreement With Retinagenix ........................................................................................................ 49
    Asset Transactions ...................................................................................................................................................................... 50
         Valocor Therapeutics Acquires Rights To Novel Dermatology Programs From QLT .............................................................. 50
         QLT Completes Sale Of Aczone To Allergan ........
								
To top